Irvine Scientific Announces New Partnership with Biotech Inc., to Distribute CRYOLOCK Vitrification Device
Irvine Scientific® , a world leader in the innovation and manufacture of Assisted Reproductive Technologies (ART), today announced a new partnership agreement with Biotech Inc., giving Irvine Scientific exclusive distribution rights for the CRYOLOCK™ vitrification device in selected countries worldwide.
Irvine Scientific is committed to providing a total system solutions approach by offering high quality vitrification media used for oocytes and embryos of all stages along with approved devices. CRYOLOCK has rapidly become one of the most highly respected vitrification devices in IVF laboratories. This new partnership enables Irvine Scientific to expand its support of approved vitrification devices.
“We are confident that the addition of CRYOLOCK will allow us to support laboratories that prefer this proven and widely used device. We are excited to provide an expanded set of vitrification devices to help customers achieve exceptional results.” said Yuichi Nagano, President and CEO, Irvine Scientific.
“This partnership significantly strengthens the existing CRYOLOCK device and demonstrates Biotech Inc.’s commitment to expanding this exceptional product for use worldwide to the infertility market”, said Jorge Parra, CRYOLOCK designer and CEO, Biotech, Inc.
Learn more about the entire line of products for Assisted Reproductive Technology at http://www.irvinesci.com/assisted-reproductive-technology
Notes to Editors
About Irvine Scientific
Irvine Scientific, a member of JX Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 40 years, Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.
About Biotech Inc.,
Established in July 2006, Biotech Inc, produces and designs instruments and tools for laboratory use in bioscience research. The Company is ISO 13485:2003 registered as a Medical Device Manufacture Company following CE Mark and FDA regulations, Biotech Inc focuses on providing high quality products with exceptional customer service in order to meet the needs of the final user
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PIERRE-FABRE23.6.2018 13:02 | pressemeddelelse
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress
SERVIER23.6.2018 10:12 | pressemeddelelse
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho
SOFTOMOTIVE22.6.2018 17:15 | pressemeddelelse
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA
TX-ASCEND-PERFORMANCE22.6.2018 16:02 | pressemeddelelse
Ascend Performance Materials Announces Price Increase for Intermediate Materials
DELTICOM-AG/MOTO-TYRES.C22.6.2018 15:43 | pressemeddelelse
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk
BOEHRINGER-INGELHEIM22.6.2018 14:02 | pressemeddelelse
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum